Skip to content

Newsroom

type
year
Climate header 2.jpg

Committed to science and sustainability: What do Orion’s science-based climate targets mean?

10/7/2024 Sustainability
orionfi_potilastarina_rintasyopa_paakuva_1500x844.jpg

Kerly Hiltunen was diagnosed with metastatic breast cancer: “I am very grateful to have been able to live this long”

10/1/2024 Your Health
Illustration image.png

Orion’s near-term climate targets approved by the Science Based Targets initiative

9/30/2024 Press release
2024_06_Faasi_004_1500x844.jpg

Jenni Laukkanen: At Orion, my views are valued and that has made me more confident

9/26/2024 We are Orion
Illustration image.png

Orion’s collaboration partner Bayer submits application to U.S. FDA for third indication of darolutamide which has become the first ever Orion-originated blockbuster

9/26/2024 Press release
Illustration image.png

Orion and Aitia enter AI-Driven Drug Discovery and Drug Simulation Collaboration in Oncology

9/25/2024 Press release
orionfi_migreeni_paakuva_1500x844.jpg

Working with a migraine is exhausting – are better migraine treatments just around the corner?

9/24/2024 Your Health
Illustration image.png

213,285 Orion Corporation A shares converted into B shares

9/20/2024 Stock exchange release
2024_06_Faasi_017_1500x844.jpg

Alessandra Rafkin: Everything I have learnt as a Phase1 trainee at Fermion will give me a strong foundation for my future career

9/19/2024 We are Orion
orionfi_terveysdata3_paakuva_1500x844.jpg

Can personal health data help predict future diseases?

9/18/2024 Your Health
2024_06_Faasi_012_FULL_1500x844.jpg

Konsta Saaranen: The Phase1 trainee programme has shown that at Orion, employees are valued and treated as equals

9/17/2024 We are Orion
Illustration image.png

Darolutamide plus androgen deprivation therapy significantly reduced the risk of radiological progression or death by 46% compared to placebo plus ADT in patients with metastatic hormone-sensitive prostate cancer

9/16/2024 Press release
Illustration image.png

Inside information: Orion upgrades full-year outlook for 2024

9/11/2024 Stock exchange release
orionfi_kiinteistopalvelut_paakuva_1500x844.jpg

Facility Management keeps pharmaceutical plants running

9/10/2024 We are Orion
orionfi_potilastarina_eturauhassyoopaa_paakuva_1500x844.jpg

Reijo Alaluusua's prostate cancer has recurred three times: “Talking about my experiences also gives me strength”

9/2/2024 Your Health
Sofia Eloranta.jpg

Sofia Eloranta: The Phase1 trainee programme leaves me with gratitude for my great team

8/28/2024 We are Orion
oriofi_tia_professori_paakuva_1500x844.jpg

AI is the drug developer’s new assistant – New drugs for pain and cancer are being developed at an accelerating pace

8/26/2024 Science and Partnering
Illustration image.png

Orion Corporation: Managers’ transactions – Satu Ahomäki

8/22/2024 Managers transactions